Skip to main content
Erschienen in: PharmacoEconomics 2/2016

01.02.2016 | Original Research Article

Cost Prediction Using a Survival Grouping Algorithm: An Application to Incident Prostate Cancer Cases

verfasst von: Eberechukwu Onukwugha, Ran Qi, Jinani Jayasekera, Shujia Zhou

Erschienen in: PharmacoEconomics | Ausgabe 2/2016

Einloggen, um Zugang zu erhalten

Abstract

Background

Prognostic classification approaches are commonly used in clinical practice to predict health outcomes. However, there has been limited focus on use of the general approach for predicting costs. We applied a grouping algorithm designed for large-scale data sets and multiple prognostic factors to investigate whether it improves cost prediction among older Medicare beneficiaries diagnosed with prostate cancer.

Methods

We analysed the linked Surveillance, Epidemiology and End Results (SEER)-Medicare data, which included data from 2000 through 2009 for men diagnosed with incident prostate cancer between 2000 and 2007. We split the survival data into two data sets (D0 and D1) of equal size. We trained the classifier of the Grouping Algorithm for Cancer Data (GACD) on D0 and tested it on D1. The prognostic factors included cancer stage, age, race and performance status proxies. We calculated the average difference between observed D1 costs and predicted D1 costs at 5 years post-diagnosis with and without the GACD.

Results

The sample included 110,843 men with prostate cancer. The median age of the sample was 74 years, and 10 % were African American. The average difference (mean absolute error [MAE]) per person between the real and predicted total 5-year cost was US$41,525 (MAE US$41,790; 95 % confidence interval [CI] US$41,421–42,158) with the GACD and US$43,113 (MAE US$43,639; 95 % CI US$43,062–44,217) without the GACD. The 5-year cost prediction without grouping resulted in a sample overestimate of US$79,544,508.

Conclusion

The grouping algorithm developed for complex, large-scale data improves the prediction of 5-year costs. The prediction accuracy could be improved by utilization of a richer set of prognostic factors and refinement of categorical specifications.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Qi R, Zhou S. A comparative study of algorithms for grouping cancer data. Hong Kong: International MultiConference of Engineers and Computer Scientists; 12–14 Mar 2014. Qi R, Zhou S. A comparative study of algorithms for grouping cancer data. Hong Kong: International MultiConference of Engineers and Computer Scientists; 12–14 Mar 2014.
2.
Zurück zum Zitat Green F, Compton C, Fritz A, Shah J, Winchester D. AJCC cancer staging atlas. New York: Springer; 2006.CrossRef Green F, Compton C, Fritz A, Shah J, Winchester D. AJCC cancer staging atlas. New York: Springer; 2006.CrossRef
3.
Zurück zum Zitat Chen D, Xing K, Henson D, Sheng L, Schwartz AM, Cheng X. Developing prognostic systems of cancer patients by ensemble clustering. J BioMed Biotech. 2009;2009:1–7. doi:10.1155/2009/632786. Chen D, Xing K, Henson D, Sheng L, Schwartz AM, Cheng X. Developing prognostic systems of cancer patients by ensemble clustering. J BioMed Biotech. 2009;2009:1–7. doi:10.​1155/​2009/​632786.
4.
Zurück zum Zitat Qi R, Zhou S. Simulated annealing partitioning: an algorithm for optimizing grouping in cancer data. Dallas: 2013 IEEE 13th International Conference on Data Mining Workshops; 7–10 Dec 2013. Qi R, Zhou S. Simulated annealing partitioning: an algorithm for optimizing grouping in cancer data. Dallas: 2013 IEEE 13th International Conference on Data Mining Workshops; 7–10 Dec 2013.
5.
Zurück zum Zitat Prorok PC, Andriole GL, Bresalier RS, Buys SS, Chia D, Crawford ED, et al. Design of the prostate, lung, colorectal and ovarian (PLCO) cancer screening trial. Control Clin Trials. 2000;21(6 Suppl):273S–309S.CrossRefPubMed Prorok PC, Andriole GL, Bresalier RS, Buys SS, Chia D, Crawford ED, et al. Design of the prostate, lung, colorectal and ovarian (PLCO) cancer screening trial. Control Clin Trials. 2000;21(6 Suppl):273S–309S.CrossRefPubMed
6.
Zurück zum Zitat Jayadevappa R, Chhatre S, Weiner M, Bloom BS, Malkowicz SB. Medical care cost of patients with prostate cancer. Urol Oncol. 2005;23(3):155–62.CrossRefPubMed Jayadevappa R, Chhatre S, Weiner M, Bloom BS, Malkowicz SB. Medical care cost of patients with prostate cancer. Urol Oncol. 2005;23(3):155–62.CrossRefPubMed
8.
Zurück zum Zitat Zeng C, Wen W, Morgans AK, Pao W, Shu XO, Zheng W. Disparities by race, age, and sex in the improvement of survival for major cancers: results from the National Cancer Institute Surveillance, Epidemiology, and End Results (SEER) Program in the United States, 1990 to 2010. JAMA Oncol. 2015;1(1):88–96. doi:10.1001/jamaoncol.2014.161.CrossRefPubMed Zeng C, Wen W, Morgans AK, Pao W, Shu XO, Zheng W. Disparities by race, age, and sex in the improvement of survival for major cancers: results from the National Cancer Institute Surveillance, Epidemiology, and End Results (SEER) Program in the United States, 1990 to 2010. JAMA Oncol. 2015;1(1):88–96. doi:10.​1001/​jamaoncol.​2014.​161.CrossRefPubMed
9.
Zurück zum Zitat Tomioka A, Tanaka N, Yoshikawa M, Miyake M, Anai S, Chihara Y, et al. Risk factors of PSA progression and overall survival in patients with localized and locally advanced prostate cancer treated with primary androgen deprivation therapy. BMC Cancer. 2015;15:420. doi:10.1186/s12885-015-1429-0.PubMedCentralCrossRefPubMed Tomioka A, Tanaka N, Yoshikawa M, Miyake M, Anai S, Chihara Y, et al. Risk factors of PSA progression and overall survival in patients with localized and locally advanced prostate cancer treated with primary androgen deprivation therapy. BMC Cancer. 2015;15:420. doi:10.​1186/​s12885-015-1429-0.PubMedCentralCrossRefPubMed
10.
Zurück zum Zitat Armstrong AJ, Tannock IF, de Wit R, George DJ, Eisenberger M, Halabi S. The development of risk groups in men with metastatic castration-resistant prostate cancer based on risk factors for PSA decline and survival. Eur J Cancer. 2010;46(3):517–25. doi:10.1016/j.ejca.2009.11.007.CrossRefPubMed Armstrong AJ, Tannock IF, de Wit R, George DJ, Eisenberger M, Halabi S. The development of risk groups in men with metastatic castration-resistant prostate cancer based on risk factors for PSA decline and survival. Eur J Cancer. 2010;46(3):517–25. doi:10.​1016/​j.​ejca.​2009.​11.​007.CrossRefPubMed
11.
Zurück zum Zitat Kohavi R. A study of cross-validation and bootstrap for accuracy estimation and model selection. Montreal: International Joint Conference on Artificial Intelligence; 20–25 Aug 1995. Kohavi R. A study of cross-validation and bootstrap for accuracy estimation and model selection. Montreal: International Joint Conference on Artificial Intelligence; 20–25 Aug 1995.
12.
Zurück zum Zitat Bang H, Tsiatis AA. Estimating medical costs with censored data. Biometrika. 2000;87(2):329–43.CrossRef Bang H, Tsiatis AA. Estimating medical costs with censored data. Biometrika. 2000;87(2):329–43.CrossRef
13.
Zurück zum Zitat Onukwugha E, Osteen P, Jayasekera J, Mullins CD, Mair CA, Hussain A. Racial disparities in urologist visits among elderly men with prostate cancer: a cohort analysis of patient-related and county of residence-related factors. Cancer. 2014;120(21):3385–92. doi:10.1002/cncr.28894.CrossRefPubMed Onukwugha E, Osteen P, Jayasekera J, Mullins CD, Mair CA, Hussain A. Racial disparities in urologist visits among elderly men with prostate cancer: a cohort analysis of patient-related and county of residence-related factors. Cancer. 2014;120(21):3385–92. doi:10.​1002/​cncr.​28894.CrossRefPubMed
15.
Zurück zum Zitat Grover SA, Coupal L, Zowall H, Rajan R, Trachtenberg J, Elhilali M, et al. The economic burden of prostate cancer in Canada: forecasts from the Montreal Prostate Cancer Model. CMAJ. 2000;162(7):987–92.PubMedCentralPubMed Grover SA, Coupal L, Zowall H, Rajan R, Trachtenberg J, Elhilali M, et al. The economic burden of prostate cancer in Canada: forecasts from the Montreal Prostate Cancer Model. CMAJ. 2000;162(7):987–92.PubMedCentralPubMed
16.
Zurück zum Zitat Geraedts AS, Fokkema M, Kleiboer AM, Smit F, Wiezer NW, Majo MC, et al. The longitudinal prediction of costs due to health care uptake and productivity losses in a cohort of employees with and without depression or anxiety. J Occup Environ Med. 2014;56(8):794–801. doi:10.1097/jom.0000000000000234.CrossRefPubMed Geraedts AS, Fokkema M, Kleiboer AM, Smit F, Wiezer NW, Majo MC, et al. The longitudinal prediction of costs due to health care uptake and productivity losses in a cohort of employees with and without depression or anxiety. J Occup Environ Med. 2014;56(8):794–801. doi:10.​1097/​jom.​0000000000000234​.CrossRefPubMed
18.
Zurück zum Zitat Leutzinger JA, Ozminkowski RJ, Dunn RL, Goetzel RZ, Richling DE, Stewart M, et al. Projecting future medical care costs using four scenarios of lifestyle risk rates. Am J Health Promot. 2000;15(1):35–44.CrossRefPubMed Leutzinger JA, Ozminkowski RJ, Dunn RL, Goetzel RZ, Richling DE, Stewart M, et al. Projecting future medical care costs using four scenarios of lifestyle risk rates. Am J Health Promot. 2000;15(1):35–44.CrossRefPubMed
19.
Zurück zum Zitat Bowen JD, Goetzel RZ, Lenhart G, Ozminkowski RJ, Babamoto KS, Portale JD. Using a personal health care cost calculator to estimate future expenditures based on individual health risks. J Occup Environ Med. 2009;51(4):449–55. doi:10.1097/JOM.0b013e3181996ceb.CrossRefPubMed Bowen JD, Goetzel RZ, Lenhart G, Ozminkowski RJ, Babamoto KS, Portale JD. Using a personal health care cost calculator to estimate future expenditures based on individual health risks. J Occup Environ Med. 2009;51(4):449–55. doi:10.​1097/​JOM.​0b013e3181996ceb​.CrossRefPubMed
Metadaten
Titel
Cost Prediction Using a Survival Grouping Algorithm: An Application to Incident Prostate Cancer Cases
verfasst von
Eberechukwu Onukwugha
Ran Qi
Jinani Jayasekera
Shujia Zhou
Publikationsdatum
01.02.2016
Verlag
Springer International Publishing
Erschienen in
PharmacoEconomics / Ausgabe 2/2016
Print ISSN: 1170-7690
Elektronische ISSN: 1179-2027
DOI
https://doi.org/10.1007/s40273-015-0368-6

Weitere Artikel der Ausgabe 2/2016

PharmacoEconomics 2/2016 Zur Ausgabe